支架内再狭窄的处理。
Management of in-stent restenosis.
机构信息
Department of Cardiology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, IIS-IP, CIBER-CV, Madrid, Spain.
Deutsches Herzzentrum München und Technische Universität München, Munich, Germany.
出版信息
EuroIntervention. 2022 Jun 3;18(2):e103-e123. doi: 10.4244/EIJ-D-21-01034.
Abstract
In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI procedures performed in current clinical practice. This State-of-the-Art review will primarily focus on the management of ISR but will begin by briefly discussing diagnosis and classification. We then move on to detail the evidence base underpinning the various therapeutic strategies for ISR before finishing with a proposed ISR management algorithm based on current scientific data.
摘要
支架内再狭窄（ISR）仍然是经皮冠状动脉介入治疗（PCI）后支架失败的最常见原因。最近的数据表明，在当前的临床实践中，ISR-PCI 约占所有 PCI 手术的 5-10%。本综述将主要关注 ISR 的管理，但首先将简要讨论诊断和分类。然后，我们详细介绍 ISR 各种治疗策略的证据基础，最后根据当前的科学数据提出 ISR 管理算法。
相似文献
1
Management of in-stent restenosis.支架内再狭窄的处理。
EuroIntervention. 2022 Jun 3;18(2):e103-e123. doi: 10.4244/EIJ-D-21-01034.
2
Stent failure: the diagnosis and management of intracoronary stent restenosis.支架失败：冠状动脉内支架再狭窄的诊断与治疗。
Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(7):501-506. doi: 10.1080/14779072.2023.2221852. Epub 2023 Jun 5.
3
In-Stent Restenosis Overview: From Intravascular Imaging to Optimal Percutaneous Coronary Intervention Management.支架内再狭窄概述：从血管内成像到最佳经皮冠状动脉介入治疗管理
Medicina (Kaunas). 2024 Mar 28;60(4):549. doi: 10.3390/medicina60040549.
4
Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis.Waksman 支架内再狭窄分类：一种基于机制的再狭窄治疗方法。
Cardiovasc Revasc Med. 2021 Dec;33:62-67. doi: 10.1016/j.carrev.2021.06.004. Epub 2021 Jun 5.
5
Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.梅毒感染经皮冠状动脉介入治疗的冠心病患者支架内再狭窄的危险因素：一项回顾性研究。
BMC Cardiovasc Disord. 2021 Sep 15;21(1):438. doi: 10.1186/s12872-021-02245-6.
6
Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up.影响冠心病经皮冠状动脉介入治疗后支架再狭窄的因素：基于 1 年随访的临床试验。
Med Sci Monit. 2019 Jan 8;25:240-247. doi: 10.12659/MSM.908692.
7
Association of serum apoA-I with in-stent restenosis in coronary heart disease.血清载脂蛋白 A-I 与冠心病支架内再狭窄的相关性。
BMC Cardiovasc Disord. 2022 Aug 4;22(1):355. doi: 10.1186/s12872-022-02762-y.
8
The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: insights from a US multicenter registry.“杂交”经皮冠状动脉介入治疗支架内再狭窄所致慢性完全闭塞病变的疗效：来自美国多中心注册研究的见解
Catheter Cardiovasc Interv. 2014 Oct 1;84(4):646-51. doi: 10.1002/ccd.25465. Epub 2014 Jul 4.
9
FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.成纤维细胞生长因子 23 与内分泌和代谢失调、心脏和肾脏功能恶化、炎症水平、狭窄程度相关，可独立预测经皮冠状动脉介入治疗（PCI）置入药物洗脱支架后冠心病患者的支架内再狭窄风险。
BMC Cardiovasc Disord. 2021 Jan 7;21(1):24. doi: 10.1186/s12872-020-01839-w.
10
Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.生物可吸收血管支架治疗冠状动脉支架内再狭窄的长期临床结果：意大利多中心经验。
Circ Cardiovasc Interv. 2016 Apr;9(4):e003148. doi: 10.1161/CIRCINTERVENTIONS.115.003148.
引用本文的文献
1
First-in-man study of coronary stent 3D reconstruction in the cathlab using rotational angiography.在导管室使用旋转血管造影术进行冠状动脉支架3D重建的首例人体研究。
Eur Heart J Imaging Methods Pract. 2025 May 28;3(2):qyaf065. doi: 10.1093/ehjimp/qyaf065. eCollection 2025 Jul.
2
Drug-Coated Balloons for Coronary Interventions: A Focused Review.用于冠状动脉介入治疗的药物涂层球囊：聚焦综述
Methodist Debakey Cardiovasc J. 2025 Aug 12;21(4):37-53. doi: 10.14797/mdcvj.1607. eCollection 2025.
3
Influence of Stent Structure on Mechanical and Degradation Properties of Poly (Lactic Acid) Vascular Stent.支架结构对聚乳酸血管支架力学性能及降解性能的影响
J Funct Biomater. 2025 Jul 6;16(7):248. doi: 10.3390/jfb16070248.
4
Stent Failure Management in Contemporary Clinical Practice.当代临床实践中的支架故障处理
Diagnostics (Basel). 2025 Jul 4;15(13):1709. doi: 10.3390/diagnostics15131709.
5
3D printing of stents via two-photon polymerization.通过双光子聚合进行支架的3D打印。
Sci Rep. 2025 Jul 2;15(1):22736. doi: 10.1038/s41598-025-07190-4.
6
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-Eluting Stent Implantation or Drug-Coated Balloon Angioplasty According to Neointima Morphology in Drug-Eluting Stent REstenosis 5: Rationale and Design of the ISAR-DESIRE 5 Trial.冠状动脉内支架置入与再狭窄——药物洗脱支架再狭窄5中根据新生内膜形态进行药物洗脱支架植入或药物涂层球囊血管成形术的随机试验：ISAR-DESIRE 5试验的原理与设计
J Cardiovasc Transl Res. 2025 Jun 30. doi: 10.1007/s12265-025-10650-x.
7
In-Stent Restenosis: Incidence, Mechanisms, and Treatment Options.支架内再狭窄：发生率、机制及治疗选择
Curr Cardiol Rep. 2025 Jun 19;27(1):96. doi: 10.1007/s11886-025-02249-0.
8
Genetic alterations in coronary cell lines exposed to sirolimus and paclitaxel.暴露于西罗莫司和紫杉醇的冠状动脉细胞系中的基因改变。
Arch Toxicol. 2025 Jun 6. doi: 10.1007/s00204-025-04101-4.
9
Safety and Efficacy of Cobalt Chromium Everolimus-Eluting Stents for Treatment of In-Stent Restenosis: An ILUMIEN IV Substudy.钴铬依维莫司洗脱支架治疗支架内再狭窄的安全性和有效性：ILUMIEN IV子研究
J Am Heart Assoc. 2025 Jun 3;14(11):e039482. doi: 10.1161/JAHA.124.039482. Epub 2025 May 22.
10
Neutrophil-to-lymphocyte ratio as a potential biomarker in predicting in-stent restenosis: A systematic review and meta-analysis.中性粒细胞与淋巴细胞比值作为预测支架内再狭窄的潜在生物标志物：一项系统评价和荟萃分析。
PLoS One. 2025 May 16;20(5):e0322461. doi: 10.1371/journal.pone.0322461. eCollection 2025.
本文引用的文献
1
Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study).生物可吸收血管支架再狭窄治疗的手术结果及一年临床结局（来自RIBS VII前瞻性研究）
Am J Cardiol. 2022 Jan 1;162:31-40. doi: 10.1016/j.amjcard.2021.09.027.
2
Clinical burden and implications of coronary interventions for in-stent restenosis.冠状动脉介入治疗支架内再狭窄的临床负担及影响
EuroIntervention. 2021 Aug 6;17(5):e355-e357. doi: 10.4244/EIJV17I5A60.
3
In-Stent CTO Percutaneous Coronary Intervention: Individual Patient Data Pooled Analysis of 4 Multicenter Registries.支架内 CT0 经皮冠状动脉介入治疗：4 个多中心注册研究的个体患者数据汇总分析。
JACC Cardiovasc Interv. 2021 Jun 28;14(12):1308-1319. doi: 10.1016/j.jcin.2021.04.003. Epub 2021 May 26.
4
Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions: Patient-Level Pooled Analysis of the Disrupt CAD Studies.血管内碎石术治疗钙化性冠状动脉病变：Disrupt CAD 研究的患者水平汇总分析。
JACC Cardiovasc Interv. 2021 Jun 28;14(12):1337-1348. doi: 10.1016/j.jcin.2021.04.015. Epub 2021 May 3.
5
Intravascular Lithotripsy for the Treatment of Calcium-Mediated Coronary In-Stent Restenoses.血管内碎石术治疗钙介导的冠状动脉支架内再狭窄。
J Invasive Cardiol. 2021 Jan;33(1):E25-E31. doi: 10.25270/jic/20.00285.
6
Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease.紫杉醇涂层器械在外周动脉疾病中的死亡率。
N Engl J Med. 2020 Dec 24;383(26):2538-2546. doi: 10.1056/NEJMoa2005206. Epub 2020 Dec 9.
7
Excimer Laser Atherectomy in Percutaneous Coronary Intervention: A Contemporary Review.准分子激光冠状动脉斑块切除术在经皮冠状动脉介入治疗中的应用：当代综述。
Cardiovasc Revasc Med. 2021 Apr;25:75-85. doi: 10.1016/j.carrev.2020.10.016. Epub 2020 Oct 27.
8
Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease.血管内碎石术治疗严重钙化冠状动脉疾病。
J Am Coll Cardiol. 2020 Dec 1;76(22):2635-2646. doi: 10.1016/j.jacc.2020.09.603. Epub 2020 Oct 15.
9
Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization.需要再次血运重建的无保护左主干冠状动脉再狭窄的长期预后影响。
JACC Cardiovasc Interv. 2020 Oct 12;13(19):2266-2274. doi: 10.1016/j.jcin.2020.07.017.
10
Combined use of intravascular lithotripsy and brachytherapy: A new approach for the treatment of recurrent coronary in-stent restenosis.血管内碎石术联合近距离放射治疗：一种治疗冠状动脉支架内再狭窄的新方法。
Catheter Cardiovasc Interv. 2021 Jun 1;97(7):1402-1406. doi: 10.1002/ccd.29332. Epub 2020 Oct 8.
Zotero 插件